Alnylam Pharmaceuticals (NASDAQ:ALNY) Issues Quarterly Earnings Results, Misses Expectations By $0.16 EPS

Alnylam Pharmaceuticals (NASDAQ:ALNYGet Rating) announced its earnings results on Thursday. The biopharmaceutical company reported ($2.00) earnings per share for the quarter, missing the consensus estimate of ($1.84) by ($0.16), MarketWatch Earnings reports. Alnylam Pharmaceuticals had a negative net margin of 101.01% and a negative return on equity of 109.21%. The business had revenue of $186.90 million for the quarter, compared to the consensus estimate of $242.82 million. During the same quarter in the previous year, the company earned ($1.71) EPS. Alnylam Pharmaceuticals’s revenue for the quarter was up 37.6% compared to the same quarter last year.

Shares of ALNY traded down $9.73 during mid-day trading on Friday, reaching $133.43. The company had a trading volume of 1,428,580 shares, compared to its average volume of 804,370. Alnylam Pharmaceuticals has a twelve month low of $125.00 and a twelve month high of $212.00. The company has a debt-to-equity ratio of 1.15, a current ratio of 4.04 and a quick ratio of 3.91. The company’s 50-day moving average is $160.27 and its 200-day moving average is $166.57. The company has a market capitalization of $16.11 billion, a P/E ratio of -17.81 and a beta of 0.85.

In other news, Director Steven M. Paul sold 15,000 shares of the stock in a transaction that occurred on Friday, April 1st. The stock was sold at an average price of $170.69, for a total value of $2,560,350.00. Following the completion of the transaction, the director now directly owns 1,000 shares of the company’s stock, valued at approximately $170,690. The sale was disclosed in a legal filing with the SEC, which is available at this link. Corporate insiders own 1.40% of the company’s stock.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Cetera Investment Advisers bought a new stake in Alnylam Pharmaceuticals during the 4th quarter worth approximately $206,000. Privium Fund Management UK Ltd bought a new stake in Alnylam Pharmaceuticals during the 4th quarter worth approximately $410,000. JustInvest LLC grew its position in Alnylam Pharmaceuticals by 17.9% during the 4th quarter. JustInvest LLC now owns 2,889 shares of the biopharmaceutical company’s stock worth $490,000 after acquiring an additional 438 shares during the last quarter. MML Investors Services LLC grew its position in Alnylam Pharmaceuticals by 9.9% during the 4th quarter. MML Investors Services LLC now owns 9,043 shares of the biopharmaceutical company’s stock worth $1,534,000 after acquiring an additional 814 shares during the last quarter. Finally, Amalgamated Bank grew its position in Alnylam Pharmaceuticals by 52.4% during the 4th quarter. Amalgamated Bank now owns 10,478 shares of the biopharmaceutical company’s stock worth $1,777,000 after acquiring an additional 3,602 shares during the last quarter. Institutional investors and hedge funds own 90.64% of the company’s stock.

Several analysts recently weighed in on the company. Guggenheim upgraded Alnylam Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $170.00 target price for the company in a research note on Thursday, February 3rd. Chardan Capital restated a “buy” rating and set a $200.00 target price on shares of Alnylam Pharmaceuticals in a research note on Friday, February 11th. Citigroup decreased their target price on Alnylam Pharmaceuticals from $223.00 to $211.00 in a research note on Friday. Oppenheimer restated an “outperform” rating and set a $205.00 target price on shares of Alnylam Pharmaceuticals in a research note on Wednesday, April 6th. Finally, StockNews.com began coverage on Alnylam Pharmaceuticals in a report on Thursday, March 31st. They issued a “hold” rating for the company. Four equities research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $218.00.

About Alnylam Pharmaceuticals (Get Rating)

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases.

See Also

Earnings History for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.